Latest (42) Full Text Articles (1570) Focus on GERD Article Summary

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
Gastroenterology, 01/24/2014  Clinical Article

Zeuzem S, et al. – The authors performed a phase IIb, randomized, double–blind, placebo–controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon–α2a (PegIFN), and ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype–1 infection previously treated with PegIFN and RBV. In treatment–experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated.

Methods

  • The authors analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66).
  • All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.

Results

  • Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%).
  • All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from PDR - powered by MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2014

1 Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study Digestive and Liver Diseases, August 4, 2014    Clinical Article

2 Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study Journal of Crohn's and Colitis, August 27, 2014    Clinical Article

3 Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years Journal of Crohn's and Colitis, September 8, 2014    Clinical Article

4 Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology, August 22, 2014    Clinical Article

5 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , September 25, 2014    Clinical Article

6 Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: A meta-analysis Clinical Gastroenterology and Hepatology , September 26, 2014    Evidence Based Medicine

7 Exclusive enteral nutritional therapy can relieve inflammatory bowel stricture in Crohn’s disease Journal of Clinical Gastroenterology, September 17, 2014    Clinical Article

8 Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: A diagnostic meta-analysis Full Text BMC Gastroenterology, July 14, 2014    Free full text    Evidence Based Medicine

9 Calcium intake and colorectal adenoma risk: Dose-response meta-analysis of prospective observational studies International Journal of Cancer, August 29, 2014    Evidence Based Medicine

10 Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ultra 1, 2, and 3 The American Journal of Gastroenterology, September 10, 2014    Clinical Article

11 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , June 25, 2014    Evidence Based Medicine    Clinical Article

12 Long-term therapeutic effect of maintenance enteral nutrition for Crohn's disease Pediatrics International, September 16, 2014    Clinical Article

13 Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: A meta-analysis The American Journal of Gastroenterology, September 24, 2014    Evidence Based Medicine

14 A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life European Journal of Gastroenterology & Hepatology, July 10, 2014    Clinical Article

15 Placebo response rate in clinical trials of fistulizing Crohn’s disease: Systematic review and meta-analysis Clinical Gastroenterology and Hepatology , September 22, 2014    Evidence Based Medicine    Review Article

16 Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study Alimentary Pharmacology and Therapeutics, September 5, 2014    Clinical Article

17 Long intestinal tube splinting really prevent recurrence of postoperative adhesive small bowel obstruction? A study of 1071 cases The American Journal of Surgery, July 23, 2014    Clinical Article

18 Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease Alimentary Pharmacology and Therapeutics, September 11, 2014    Clinical Article

19 The management of Crohn's disease and ulcerative colitis during pregnancy and lactation Alimentary Pharmacology and Therapeutics, September 12, 2014    Review Article

20 Plasma 25-hydroxyvitamin D and risk of colorectal cancer after adjusting for inflammatory markers Cancer Epidemiology, Biomarkers & Prevention, August 15, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all our site's content (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from our site and our sponsors
View Samples and Register